The total number of records retrieved from this search are 17. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_836	Virus nameHerpes simplex virus	Virus strainHSV-G207	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant of both copies of gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNatural	Origin of cell lineCellosaurus cell line	Cell lineHCT-8	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayBeta galacosidase colorimetric assay	In-vitro virus concentration0.1 MOI	In-vitro result76% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID10428757
IDOV_2412	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-8	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro resultNo cell killing after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2413	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-8	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro resultNo cell killing after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2414	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-8	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro resultNo cell killing after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2415	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-8	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro result50% cell killing after day 7	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2416	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-8	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro result40% cell survival after day 9	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2452	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-8	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result100% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2453	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-8	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result100% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2454	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-8	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result100% cell survival after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2455	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-8	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result70% cell survival after day 7	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2456	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-8	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result30% cell survival after day 7	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2490	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-8	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result80% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2491	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-8	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result60% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2492	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-8	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result20% cell survival after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2493	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-8	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result15% cell survival after day 7	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2494	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-8	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 9	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_4286	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal adenocarcinoma	Cell lineHCT-8	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result35.2 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347